Humpback whale in Pacific Ocean, newly born giraffe calf and more...
Humpback whale in Pacific Ocean, newly born giraffe calf and more...
Three-time U.S. women's hockey Olympian Kacey Bellamy, a member of the popular 2018 gold-medal-winning team, announced her retirement on Tuesday. The 34-year-old Bellamy played 130 games over 15 years with the national team and had 11 goals and 38 assists. "Hockey has given me the most incredible memories, and as tough of a decision that this is, I know in my heart it is right," Bellamy said in her announcement.
The Multiple Myeloma pipeline is majorly thriving owing to the several different companies developing novel and sophisticated blockbuster drugs, increasing R&D, increasing global prevalence, better awareness and appropriate diagnosis in patients.Los Angeles, USA, May 18, 2021 (GLOBE NEWSWIRE) -- Multiple Myeloma Pipeline Analysis Demonstrates Stunning Growth with a Gamut of Pharma Companies Involved Worldwide The Multiple Myeloma pipeline is majorly thriving owing to the several different companies developing novel and sophisticated blockbuster drugs, increasing R&D, increasing global prevalence, better awareness and appropriate diagnosis in patients. DelveInsight’s ‘Multiple Myeloma Pipeline Insights’ report provides a holistic view of the pipeline therapies that are under development in preclinical as well as clinical stages of development, and growth prospects across the Multiple Myeloma domain. Some of the key takeaways from the Multiple Myeloma Pipeline report: Multiple Myeloma Pipeline report offers a comprehensive analysis of 80+ key players and 80+ key therapies.The report lays a comprehensive analysis of the Multiple Myeloma pipeline therapies and key pharmaceutical companies including Kiadis Pharma, CASI Pharmaceuticals, NOXXON Pharma, MorphoSys), Sana Biotechnology, Ayala Pharmaceuticals, Cellectar Biosciences, Bristol-Myers Squibb, Poseida Therapeutics, AbbVie/Genentech, Jansesn Research and Development, Biotest AG, Teneobio, iCell Gene Therapeutics, Juno Therapeutics, Arch Oncology, Regeneron Pharmaceuticals, Incyte Corporation, NexImmune Inc., Chongqing Precision Biotech, Novartis, CASI Pharmaceuticals, Ionis Pharmaceuticals, AgenTus Therapeutics, Biohaven Pharmaceuticals, CRISPR Therapeutics, Pfizer, GlaxoSmithKline, Seagen Inc., Heidelberg Pharma, Bluebird Bio, C4 Therapeutics, Inc., Hoffmann-La Roche, Phosplatin Therapeutics, Arcellx, Inc., HitGen Inc., Boehringer Ingelheim, I-Mab Biopharma, Celyad Oncology, Amgen and others.Out of all the emerging therapies Ciltacabtagene Autoleucel is expected to emerge as the trailblazer owing to the treatment of Multiple Myeloma. The Janssen Pharmaceutical Companies of Johnson & Johnson submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. Multiple Myeloma pipeline comprises K NK004 (Kiadis Pharma), CID 103 (CASI Pharmaceuticals), NOX-A12 (NOXXON Pharma), TJ202 (I-MAB Biopharma), SG221 (Sana Biotechnology), AL 102 (Ayala Pharmaceuticals), CLR 131 (Cellectar Biosciences), Nivolumab (Bristol-Myers Squibb), P BCMA 101 (Poseida Therapeutics), Venetoclax (AbbVie/Genentech), and several others in the different therapeutic stage of development. Some of the other novel therapies are in the Multiple Myeloma pipeline including TNB-383B, ONC201, AO-176, JCARH125, REGN5458, INCB001158, TAK-573, NEXI-002 T Cells, PHE885, CID-103, ION251, EMB-06, agenT-797, CTX120, PF-06863135, SEA-BCMA, AEVI-007, HDP-101, bb21217, CFT7455, RO7425781, PT-112, HG146, CYAD-211, AMG 701 and others. CAR-T, or chimeric antigen receptor T-cells, a new form of cancer immunotherapy is advancing rapidly in the treatment of patients with Multiple myeloma and several other advanced cancer. Currently, the B-cell maturation antigen (BCMA) is the major target for CAR T cell therapies. BCMA has several advantages as a therapeutic target in myeloma. It is expressed exclusively on plasma cells and in particularly large quantities on plasma-turned-myeloma cells.TNB-383B is a BCMA x CD3 T-cell engaging bispecific antibody being studied in relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy. TNB-383B is being developed by TeneoOne through Phase 1. AbbVie holds the exclusive right to acquire TeneoOne and lead subsequent global development and commercialization of TNB-383B. Got queries? Want to know more? Request for Sample @ Multiple Myeloma Pipeline Insights Multiple Myeloma is a malignant disorder characterized by uncontrolled proliferation of clonal plasma cells causing a wide variety of complications leading to organ dysfunction and eventually death. It is the second most prevalent hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from an accumulation of terminally differentiated monoclonal plasma cells (PC) in the bone marrow. Reach out @ Multiple Myeloma Pipeline: Novel therapies and emerging technologies The Multiple Myeloma pipeline report proffers a holistic view of the business opportunities, threats, prospective collaborations and agreements, strong competitors, growth strategies, failed as well as discontinued drugs. Multiple Myeloma Pipeline: Drug Portfolio DrugCompanyPhaseMoARoAK NK004Kiadis PharmaPreclinicalAntibody-dependent cell cytotoxicity; Immunologic cytotoxicity; Natural killer cell replacementsNACID 103CASI PharmaceuticalsIAntibody-dependent cell cytotoxicity; Natural killer cell stimulants; T lymphocyte stimulantsNANOX-A12NOXXON PharmaIIChemokine CXCL12 inhibitorsNATJ202 I-MAB BiopharmaIIIAntibody-dependent cell cytotoxicity; Phagocyte stimulantsIntravenousAPG-2575Ascentage PharmaIIProto-oncogene protein c-bcl-2 inhibitorsparenteralAL 102Ayala PharmaceuticalsIAmyloid precursor protein secretase inhibitorsOralCLR 131Cellectar BiosciencesIIIonising radiation emittersIntravenousNivolumab Bristol-Myers SquibbIIIAntibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulantsIntravenousP BCMA 101Poseida TherapeuticsIIImmunologic cytotoxicity; T lymphocyte replacementsParenteralVenetoclax AbbVie/GenentechIIIApoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitorsOralRG6160GenentechIAntibody-dependent cell cytotoxicity; T lymphocyte stimulantsIntravenousHPN-217Harpoon TherapeuticsI/IIImmunologic cytotoxicity; T lymphocyte replacementsIntravenousSAR442085SanofiIAntibody-dependent cell cytotoxicity; Apoptosis stimulants; Phagocyte stimulantsIntravenousPF-06863135PfizerIIAntibody-dependent cell cytotoxicity; T lymphocyte stimulantsParenteralRAPA-201 Autologous T cellsRapa TherapeuticsIIImmunologic cytotoxicity; T lymphocyte replacementsParenteral The report lays down a complete coverage of the therapeutics by development stage, product type, route of administration, molecule type, and MOA type for Multiple Myeloma across the complete product development cycle, including all clinical and non-clinical stages. Multiple Myeloma Therapeutic Assessment By Product Type MonoCombination By Stage Discovery Pre-clinicalINDPhase IPhase IIPhase IIIPre-registration By Molecule Type Small Molecule Gene TherapyStem Cell Therapy By Route of Administration IntravenousInhalationOralSubcutaneous By Mechanism of Action Antibody-dependent cell cytotoxicityProgrammed cell death-1 receptor antagonistsApoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitorsIonizing radiation emittersChemokine CXCL12 inhibitorsAmyloid precursor protein secretase inhibitorsImmunologic cytotoxicity; T lymphocyte replacementsImmunologic cytotoxicity; Natural killer cell replacements By Targets Protease Multiple Kinase By Stage and Route of AdministrationBy Stage and Product Type Scope of the Report Coverage: GlobalKey Players: Kiadis Pharma, CASI Pharmaceuticals, NOXXON Pharma, MorphoSys), Sana Biotechnology, Ayala Pharmaceuticals, Cellectar Biosciences, Bristol-Myers Squibb, Poseida Therapeutics, AbbVie/Genentech, Janssen Research and Development, Nanjing Legend Biotech, Genenta Science, Biotest AG, Teneobio, iCell Gene Therapeutics, Juno Therapeutics, Arch Oncology, Regeneron Pharmaceuticals, Incyte Corporation, NexImmune Inc., Chongqing Precision Biotech, Novartis, CASI Pharmaceuticals, Ionis Pharmaceuticals, AgenTus Therapeutics, Biohaven Pharmaceuticals, CRISPR Therapeutics, Pfizer, GlaxoSmithKline, Seagen Inc., Heidelberg Pharma, Bluebird Bio, C4 Therapeutics, Inc., Hoffmann-La Roche, Phosplatin Therapeutics, Arcellx, Inc., HitGen Inc., Boehringer Ingelheim, I-Mab Biopharma, Celyad Oncology, Amgen and othersKey Multiple Myeloma Pipeline Therapies: TNB-383B, ONC201, AO-176, JCARH125, REGN5458, INCB001158, TAK-573, NEXI-002 T Cells, PHE885, CID-103, ION251, EMB-06, agenT-797, CTX120, PF-06863135, SEA-BCMA, AEVI-007, HDP-101, bb21217, CFT7455, RO7425781, PT-112, HG146, CYAD-211, AMG 701, Nivolumab, ventoclax, RAPA-201 autologous T cells, K NK004, CID 103, NOX-A12, TJ202, APG-2575, AL 102, CLR 131 and others. Reach out @ Multiple Myeloma Pipeline: Novel therapies and emerging technologies Table of Contents 1Introduction2Executive Summary3Multiple Myeloma Overview4Multiple Myeloma Pipeline Pipeline Therapeutics5Multiple Myeloma Pipeline Therapeutic Assessment6Multiple Myeloma – DelveInsight’s Analytical Perspective7In-depth Commercial Multiple Myeloma Pipeline Assessment8Multiple Myeloma Collaboration Deals9Late Stage Multiple Myeloma Pipeline Products (Phase III and Preregistration)10Mid-Stage Multiple Myeloma Pipeline Products (Phase II)11Pre-clinical and Discovery Stage Multiple Myeloma Pipeline Products12Inactive Multiple Myeloma Pipeline Products13Multiple Myeloma Key Companies14Multiple Myeloma Key Products15Multiple Myeloma Unmet Needs16Multiple Myeloma Market Drivers and Barriers17Multiple Myeloma Future Perspectives and Conclusion18Multiple Myeloma Pipeline Analyst Views20Appendix Visit to know more of what’s covered @ Multiple Myeloma Emerging Therapies Related Reports Multiple Myeloma MarketDelveInsight’s ‘Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast—2030’ report. Multiple Myeloma Epidemiology ForecastDelveInsight’s ‘Multiple Myeloma (MM)- Epidemiology Forecast to 2030’ report. Car T Cell Therapy For Multiple Myeloma MarketDelveInsight’s ‘CAR T-Cell Therapy for Multiple Myeloma-Market Insights and Market Forecast-2030’ report. Refractory Multiple Myeloma MarketDelveInsight's "Refractory Multiple Myeloma - Market Insights, Epidemiology, and Market Forecast-2030" report. Relapsed Refractory Multiple Myeloma MarketDelveInsight's "Relapsed/Refractory Multiple Myeloma (RRMM) - Market Insights, Epidemiology, and Market Forecast-2030" report. Triple Refractory Multiple Myeloma MarketDelveInsight's "Triple-refractory Multiple Myeloma - Market Insights, Epidemiology, and Market Forecast-2030" report. Higher Risk Chronic Myelomonocytic Leukemia MarketDelveInsight's "Higher-Risk Chronic Myelomonocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2030" report. Related Posts Multiple Myeloma Market Insights Multiple Myeloma Therapies MarketRare Cancer Market Outlook About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News CONTACT: Contact Us Shruti Thakur firstname.lastname@example.org +1(919)321-6187 www.delveinsight.com
President Biden declared in his inaugural Congressional address that his administration will spend upwards of $2 trillion to upgrade America’s roads, public transit and broadband. He would cover the tab by raising taxes on the highest earners, a prospect Republicans are adamantly opposed to. One way to help break the stalemate on funding could be through a little-known immigration program: the EB-5 visa — referred to as the investor visa.
WASHINGTON (AP) — President Joe Biden and administration officials have encouraged Prime Minister Benjamin Netanyahu and other top Israeli officials to wind down the bombardment of Gaza, a person with knowledge of the discussions said Tuesday, as the Israeli and Palestinian death tolls mounted and pressure grew on Biden to move more forcefully to stop the fighting. Top Biden administration officials underscored to the Israelis on Monday and Tuesday that time is not on their side in terms of international objections to nine days of Israeli airstrikes and Hamas rockets, and that it is in their interest to wind down the operations soon, according to the official, who was not authorized to comment publicly on the private talks and spoke on condition of anonymity. The account shows Biden administration officials going further privately in messaging to Netanyahu than they have previously revealed. A White House readout of a Biden call to Netanyahu on Monday said Biden had expressed support for a cease-fire, but said nothing about the U.S. urging Israel to bring fighting to a close. The fighting has killed at least 213 Palestinians and 12 people in Israel, and tested both Biden's reluctance to publicly criticize Israel and his administration's determination not to bog down its foreign policy focus in Middle East hot spots. The Palestinian ambassador to the United Nations on Tuesday challenged the Biden administration to show any results from what it is calling its quiet diplomacy to stop the new Israeli-Hamas battles. Ambassador Riyad Mansour pointed to the U.S. repeatedly blocking a U.N. Security Council action on the conflict, and he urged the Biden administration to do more. “If the Biden administration can exert all of their pressure to bring an end to the aggression against our people, nobody is going to stand in their way,” Mansour said. France, in consultation with Egypt and Jordan, on Tuesday was preparing a U.N. Security Council resolution calling for a cease-fire, Zhang Jun, China's U.N. ambassador, and other diplomats told reporters. The move to put the U.N.'s most powerful body behind a demand for Israel and Hamas to stop hostilities came after the U.S. repeatedly blocked what would have been a unanimous Security Council statement expressing concern about the fighting. The White House has so far resisted the calls for ramping up public pressure on Netanyahu. It has made the calculation that Israelis will not respond to international resolutions or public demands by the U.S. and that its greatest leverage is behind-the-scenes pressure, according to the person familiar with the administration’s discussions. The person said that the Israelis have signaled that it is possible their military campaign could end in a matter of days. The effort to press U.S. ally Israel to find an endgame to the military campaign in Gaza came amid a split this week among House Democrats on whether to step up pressure for a cease-fire and call for more forceful U.S. diplomacy to end the fighting. Democrats on the House Foreign Affairs Committee weighed — but on Tuesday shelved — writing Biden to demand that he delay a pending $735 million sale of precision-guided missiles to Israel. Dozens of progressive and mainstream Democratic lawmakers already have called for a cease-fire between Israel and Gaza's Hamas militants, and some Democrats are demanding Biden push harder for an end to fighting. Committee member Rep. Joaquin Castro, D-Texas, was among the Democrats seeking a harder line, saying he has “serious concerns about the timing of this weapons sale, the message it will send to Israel and the world about the urgency of a cease fire.” He said late Monday that the Biden administration “must use every diplomatic tool to de-escalate this conflict and bring about peace.” Committee chair Rep. Gregory Meeks, D-N.Y. said the lawmakers expect an administration briefing Wednesday on the crisis. House Majority Leader Steny Hoyer on Tuesday acknowledged the difference between a growing number of progressive Democrats and the Biden administration on the U.S. approach to the conflict, but played it down. “Every Democrat, and I think every Republican, wants to minimize the exposure of both sides in Gaza and in Israel,” Hoyer told reporters. “There’s a difference about how that can be done.” Biden did not join in the calls by some of his party's lawmakers and by many foreign governments to demand a cease-fire, however. In talks with the Israelis, administration officials have pointed to Hezbollah’s stature rising in the region after their 34-day war with Israel in 2006 to make the case for limiting the time of the military action. But Israeli officials have argued to the administration that a slightly prolonged campaign to degrade Hamas’ military capabilities is necessary and in their interest, according to the person familiar with the talks. Hamas operates in the crowded Gaza Strip, a 25-by-6-mile (40-by-10-kilometer) territory crowded with more than 2 million people. Hamas has sought to portray their rocket barrages as a defense of Jerusalem. The Israelis have made the case to Biden administration officials that that message is losing resonance as mob violence against Arabs in mixed Israeli cities, including Lod, has been tamped down. Administration officials are defending Biden's decision to avoid ratcheting up public pressure on Israel for its role in the fighting. The U.S. this week killed a proposed U.N. Security Council statement that would have expressed concern for civilian deaths and raised the issue of a cease-fire. “The president has been doing this long enough ... to know sometimes diplomacy has to happen behind the scenes,” White House press secretary Jen Psaki told reporters Tuesday. She spoke as Biden headed to a Ford electric vehicle site in Michigan to promote a green infrastructure plan. Pressure on the White House to do more in the Israeli-Palestinian conflict dogged the trip, with protesters in communities with large populations of Arab Americans shouting condemnation of Biden. ___ Knickmeyer reported from Oklahoma City. Associated Press writers Matthew Lee and Edith Lederer contributed to this report. Ellen Knickmeyer, Aamer Madhani And Lisa Mascaro, The Associated Press
The sports star was riding her bike when the driver drifted into the bike lane and collided with her, the Lakewood Police Department said in a statement
House Minority Leader Kevin McCarthy has been rightly ridiculed for his shifting positions on whether Donald Trump bears responsibility for the Jan. 6 siege of the Capitol by crazed Trump supporters.
Pro-Palestine demonstrators marched through midtown Manhattan on May 18, stopping in front of the New York offices of the American Israel Public Affairs Committee (AIPAC).AIPAC is a lobbying group representing pro-Israel interests in the US, and is often the target of critics of the country’s policies. During Israel’s current campaign in Gaza, AIPAC has defended the military intervention, and said that Hamas uses civilians as “human shields.”On Tuesday, health officials in Gaza said that at least 213 people have been killed and more than 1,400 injured inside the Palestinian enclave since the start of Israeli strikes on May 10. At least 12 people have been reported killed inside Israel after militants in Gaza began firing thousands of rockets.On Tuesday, protesters marched through parts of midtown Manhattan, stopping in front of AIPAC’s Third Avenue offices, where this video was taken. Credit: Jason Rosenberg via Storyful
OTTAWA — Canada's chief public health officer said Tuesday she expects Canadians who got the Oxford-AstraZeneca in the first round of vaccinations will be able to choose which vaccine they get for their second dose.Dr. Theresa Tam's comments came hours after a small Spanish study on mixing and matching vaccines reported that giving a Pfizer-BioNTech shot for the second dose after AstraZeneca is safe and produced twice as many antibodies as a second dose of AstraZeneca.The National Advisory Committee on Immunization, known as NACI, is still awaiting further data from another mixing-and-matching study underway in the United Kingdom, but Tam said advice on second doses should be ready before most people are due to get their second vaccination."It is likely that people in Canada who've received one dose of AstraZeneca will have a choice for their second dose," she said at a news conference from Ottawa.The decision could affect more than 2.1 million people vaccinated with AstraZeneca, and is related mainly to safety issues for that vaccine. Tam said there are now 21 confirmed cases of vaccine-induced thrombotic thrombocytopenia, or VITT, the rare but serious blood-clotting disorder potentially linked to AstraZeneca.Another 13 cases are under investigation. Three women have died.NACI advised last month that people at low risk of getting COVID-19 should get either Pfizer or Moderna, leading many to wonder if they should risk getting another dose of AstraZeneca.Tam and Health Minister Patty Hajdu said there will be enough doses of vaccine for AstraZeneca recipients regardless of which kind it is."I think everybody's anxious to make sure people who got the first dose of AstraZeneca do have the ability to get that second dose," said Tam.She has said that a less socially distanced summer will depend on curbing case rates, reducing hospital patients and getting more vaccines into arms. She said if 75 per cent of eligible Canadians — right now that's people over 12 — get one dose, and 20 per cent get both doses, the summer could hold the promise of backyard barbecues, camping, outdoor picnics and evenings out with friends on a restaurant patio."We're not there yet, but I am really hopeful because of how fast some of the vaccines are going in the arms," she said.On Tuesday, about 17.6 million Canadians had at least one dose, or 55 per cent of people over the age of 12. Another 1.5 million have both doses, about 4.5 per cent of the eligible group.Many provincial governments aren't following the national suggestions. Saskatchewan Premier Scott Moe, who said 75 per cent of people over 40 now have one dose, intends to move to step one reopening as planned May 30.That means in less than two weeks, restaurants can open for limited indoor services, and people can socialize with up to 10 people indoors or outdoors at private homes.Saskatchewan said it intends to start vaccinating teenagers in early June, hoping to have most 12- to 17 year-olds vaccinated by the time school ends for the summer. The province also released a plan for starting second doses, cutting the expected wait from 16 weeks to 13 weeks for most people.In British Columbia, health officials said second doses of COVID-19 vaccines may be given sooner than previously expected with more information to come early next month. B.C. reported 411 new cases of COVID-19 on Tuesday.Quebec said Tuesday 75 per cent of all adults have either received one dose or have their first appointment scheduled. Quebec Premier François Legault unveiled a detailed, months-long reopening plan that will start in the next two weeks with most Quebec schools fully reopening, eliminating all of the province's curfews on May 28, and allowing people to gather with up to eight people in their backyards.Legault said if 75 per cent of Quebecers over the age of 12 get both doses by the end of August, the provincewide public face mask requirement will be lifted.Tam said it's not just about vaccines though, but also the level of COVID-19 around, and there were many positive signs on that front as well.While Canada reached the grim milestone of 25,000 deaths from COVID-19 on Tuesday morning, the number of daily deaths has fallen in the last week from 49 to 43.The average number of new daily cases fell from 7,275 to 5,600. Hospitalizations are down from 4,000 to about 3,600, and the number of people in intensive care fell from 1,400 to 1,300, in the last week, but Tam said both those markers are still higher than is comfortable.She warned that reopening things too soon could be damaging."We have to be very cautious about that downward path," she said. "I can't tell you right now when we'll get to the bottom of this. Last time we only got two-thirds of the way down the curve and then with some relaxation of restrictive measures we went back up again. And so there's still a chance that could happen if we're not careful."This report by The Canadian Press was first published May 18, 2021. Mia Rabson, The Canadian Press
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Braxia Scientific Corp. f/k/a Champignon Brands Inc. ("Champignon") (OTC: SHRMF) between March 27, 2020 and February 17, 2021, inclusive (the "Class Period") of the important June 9, 2021 lead plaintiff deadline in the securities class action commenced by the firm.
TransAlta Renewables Inc. ("TransAlta Renewables" or the "Company") (TSX: RNW) held its virtual Annual Meeting of Shareholders on May 18, 2021. A total of 201,321,092 Common Shares, representing 75.44% of the shares outstanding, were represented in person and by proxy at the meeting.
VANCOUVER — The stakes may be low, but coach Travis Green says his Vancouver Canucks are playing hard to finish out the season. The Canucks took points from a third-straight game on Tuesday, beating the Calgary Flames 4-2. “We don’t go out on the ice to lose hockey games," Green said. "We want guys that are competitive, we want guys that play to win. And it’s good that we’re doing that.” It was a busy end to the afternoon, with three goals coming in the game's final four minutes. Calgary (25-27-3) was down 3-0 when Adam Ruzicka went into the end boards late in the third period. The Flames forward continued battling for the puck, eventually getting it to a waiting Milan Lucic. Lucic then dished it to Andrew Mangiapane at the top of the crease and the Flames left-winger snapped it for Calgary's first of the day 16:38 into the period. The goal was Mangiapane's 17th of the season and extended his scoring streak to four games. He has two goals and four assists across the stretch. Eighty-two seconds later, Matthew Tkachuk sent a puck sailing I in past Canucks goalie Thatcher Demko to bring the Flames within one. Brock Boeser restored Vancouver's (23-28-4) two goal lead with 18 seconds left on the clock, sending a bouncing shot through the neutral zone and into the empty Calgary net to make it 4-2. The strike was the right-winger's team-leading 23rd goal of the season. Boeser also had an assist on the day and extended his point streak to four games. Travis Hamonic also put up two points for the Canucks, opening the scoring 9:43 into the first period and assisting on Boeser's empty-net tally. The former Flames defenceman has played some "really good hockey" since returning from broken ribs at the end of February, Green said. "When he first got here it took him a little time, he really hadn’t skated for almost a year and then he got hurt," the coach said. "While he got hurt, he got to know his teammates a little more and got his legs under him, got a bit more comfortable as far as skating. And he’s been everything we thought and hoped he’d be." Tyler Myers also had a goal and an assist for the Canucks on Tuesday, and rookie forward Nils Hoglander scored his 13th of the year. Demko stopped 38 shots and seemed poised for a shutout until late in the third period. “It was a good 60 minutes. Obviously they pushed a little bit there in the third but you had to expect that and I thought we handled it pretty well," the goalie said. Louis Domingue played his first game for the Flames and stopped 20-of-23 shots. The 29-year-old goaltender said Tuesday's game may have been his last in the NHL. "In the back of my mind this might be my last game, this might not be," he said. "I don't know what the next year is going to look like for me but I'm definitely glad I get to play and as the game went on, I definitely felt more comfortable and felt more like I belong." Domingue said when he signed with the Flames as a free agent in October, he believed he'd be playing more. Instead, he's spent much of the year on Calgary's taxi squad. "To be honest I don't think that taxi squad was very good for any players," he said. "I don't think that was a good solution for anyone and it's pretty unfortunate, because we saw a lot of guys that didn't get a lot of playing time that played in the minors and whatnot so pretty disappointed with the taxi squad situation. But it is what it is." The Flames and Canucks will wrap up their seasons Wednesday with a matinee in Calgary. Calgary holds a 6-3 lead in the 10-game season series between the two sides. NOTES: Both Vancouver and Calgary were 0 for 3 on the power play. … Domingue's last game action was on March 1, 2020 when he played for Vancouver. … Canucks right-winger Will Lockwood made his NHL debut. Vancouver selected the 22-year-old from Royal Oak, Mich., 64th overall in the 2016 draft. Lockwood had four goals and seven assists in 24 American Hockey League games this season. This report by The Canadian Press was first published May 18, 2021. Gemma Karstens-Smith, The Canadian Press
As vaccination numbers across Canada rise, provinces are preparing to start looking ahead, if vaccine targets can be met.
ARLINGTON, Texas (AP) — Gleyber Torres could be back in the New York Yankees lineup as early as Wednesday, a week after the fully vaccinated shortstop tested positive for COVID-19. Manager Aaron Boone said Tuesday that Torres had been cleared by Major League Baseball's joint committee and was already en route to Texas to rejoin the team. The shortstop could potentially be activated Wednesday. Asymptomatic vaccinated people can be cleared to return if they test negative twice. Torres was the only player among nine total positives within the Yankees traveling party since last week, which included three coaches and five staffers. Boone said Torres is the only one in that group cleared to return. The shortstop had been quarantining in Tampa, where he worked out Monday and Tuesday before before heading to Texas. Torres tested positive for COVID-19 despite being fully vaccinated and having previously contracted the coronavirus during the offseason. The three coaches and four of the traveling staffers were also breakthrough positives, meaning they tested positive despite being fully vaccinated. ___ More AP MLB: https://apnews.com/hub/MLB and https://twitter.com/AP_Sports The Associated Press
Carl Lentz was fired from Hillsong Church in November due to "moral failures," Brian Houston previously told PEOPLE
REGINA — The Saskatchewan Health Authority says it will shift COVID-19 vaccine appointments to pharmacies and clinics run by Indigenous Services Canada to make room for school immunizations. The province says it wants to make sure students can be immunized before the end of the school year. Officials with the health authority say they will start delivering COVID-19 vaccines in elementary and high schools in early June, though no dates have been finalized. "We are working with the local schools to make sure those align as much as possible with school schedules and other commitments like graduations and exams," said Derek Miller, the authority's executive director of infrastructure management. The health authority, he said, wants to operate in schools during the normal school week to take advantage of having a "captive audience" of students who can all be vaccinated at one-time. CEO Scott Livingstone added that parents will play a key role in this stage of the vaccine rollout. "Many of you (parents) have yourself received vaccines, and we encourage you to talk with your children to address any questions or fears they may have in advance of their immunizations," he said Tuesday. "Celebrate with your kids when they say yes to COVID immunization and choose to protect themselves, their family and our province." The province said parental consent will be needed for children to receive the vaccine. It has promised more than 90,000 vaccines in total for children 12 and older. Youth are currently only eligible to receive the Pfizer-BioNTech vaccine. While the in-school rollout is taking place, Livingstone said the health authority will transfer booked appointments to pharmacies and Indigenous Services Canada. Students who are home-schooled or want a vaccine before their school offers it will be able, like adults, to get their shot at a pharmacy or a clinic. Saskatchewan also laid out its strategy Tuesday for delivering second doses. Starting Monday, residents who are 85 and older or those who received their first dose by Feb. 15 are eligible to book their second dose. Residents who are 70 and older or those who received their first dose by March 15 will be eligible for their second dose by the end of May. Health Minister Paul Merriman praised young people in the province for "doing their part" to get their shots as the province delivered record-high numbers of vaccines over the weekend. "Fifty-nine per cent of all Saskatchewan adults have now received their first shot," said Merriman. "To put that in context, the U.S. today is at 60 per cent of all adults with one shot, according to the CDC. Not long ago, we were way behind the U.S." This report by The Canadian Press was first published on May 18, 2021. — By Julia Peterson in Saskatoon. The Canadian Press
(Bloomberg) -- Website-hosting service Squarespace Inc. was assigned a reference price of $50 a share by the New York Stock Exchange as it prepares for its trading debut in a direct listing.Squarespace’s shares will begin trading Wednesday without the company raising any capital. As with previous direct listings, the company won’t issue new shares at a set price. Instead, current investors can simply begin selling shares based on demand when trading opens.The company is joining a cadre of technology-oriented firms that have gone public through direct listings, most recently cryptocurrency exchange Coinbase Global Inc. and online game maker Roblox Corp. this year. Palantir Technologies Inc. and Asana Inc. debuted through direct listings last year, following a trail blazed by Spotify Technology SA and Slack Technologies Inc. before them.Led by founder and Chief Executive Officer Anthony Casalena, Squarespace competes against publicly traded rivals Wix.com Ltd. and GoDaddy Inc., among others. The New York-based company is backed by investors including General Atlantic, Index Ventures and Accel.Setting a reference price is a requirement for trading to begin. Unlike the share price in a standard initial public offering, it isn’t a direct indicator of the company’s market capitalization because it’s a guide rather than a sale price. Still, at $50 a share, Squarespace would have a market value of about $6.8 billion based on the outstanding shares listed in its filings, not including employee stock options.Squarespace raised funding in March at an enterprise value of $10 billion, an amount that would have included options and similar holdings.While investment banks don’t underwrite direct listings as they do IPOs, they do advise the company on the listing. Squarespace is working with with banks including Goldman Sachs Group Inc. and JPMorgan Chase & Co., according to its filings with the U.S. Securities and Exchange Commission. The company’s shares are expected to trade on the NYSE under the symbol SQSP.E-Commerce ExpansionSquarespace had 3.7 million unique subscriptions as of Dec. 31 and is expanding beyond web hosting to e-commerce, according to its filing.It had a net income of about $31 million on revenue of $621 million last year, compared with $58 million on revenue of $485 million in 2019, according to its filing.Its e-commerce business had 2020 revenue of $143 million, a 78% increase over the previous year, according to the filing. Its growth plans include expanding it customer base -- especially internationally -- and deepening its commerce offerings.The company acquired restaurant-services provider Tock for more than $400 million in March. Squarespace paid a mix of cash and stock for the Chicago-based company, which provides technology for online reservations, takeout and other services. That followed 2019 deals for Unfold Creative LLC and Acuity Scheduling Inc.Squarespace will pursue strategic acquisitions to accelerate key platform, product and marketing initiatives, it said in its filing.Casalena will continue to control the company through his 76% ownership of the company’s Class B shares, which carry 10 votes each compared with one each for the Class A shares that will be listed, according to the filings.(Updates with revenue in eighth paragraph)More stories like this are available on bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
As flood waters receded, Derek Erasmus returned to his home in Fort Simpson to survey the damage — silt on nearly every surface, and items toppled blocking access to rooms. When the water came up over the first floor, Erasmus was worried most about two items: his grandfather's bible, and his other grandfather's dry meat bag. He inherited both items when they died, and those were the two things he was worried about as the floodwaters rose. The bible was wet, but the dry meat bag unscathed. Derek Erasmus cleaning up and drying out his grandfather’s bible. (Loren McGinnis/CBC) 'We still love it here' An estimated 700 residents were forced to evacuate the community over a week ago when the Liard River broke, with some fleeing to Fort Smith, Hay River and Norman Wells. Flood waters have since receded, and community members have returned to assess the damage. Erasmus's garage and rental unit filled with nearly a metre of water, soaking his tools and his wife's pottery studio. Without insurance, rebuilding will be a considerable effort, he said. "We'll have to clean it all out and repair everything. New flooring, drywall. I think we'll have to replace insulation," he said. They'll have to relocate their mechanical room upstairs, in case the community ever floods like this again, he said. Even though the Dehcho (Mackenzie River) is powerful, and though Erasmus has been flooded out before, he's not planning to move any time soon. "We still love it here. It's nice to be by the river." They've been staying with their parents on higher ground, and their young daughter has been upset by the flood. The waters also displaced one of their renters and the revenue they get from a suite, which went underwater. Walking through the house, Erasmus tells CBC the silt has affected an entire level of their house. "Pretty dirty, lots of silt on the ground," he said. 'Everyone pulled together' The public works crew having a coffee and making a plan for the morning.(Loren McGinnis/CBC) Erasmus says he and his neighbours are trying to remain positive. "Everyone pulled together.… Everyone got fed, everyone got housed. It's been positive for the community to come together, especially [with] COVID-19… there's been no drum dances or feasts." Erasmus said donations have come in from all over the North from businesses and individuals and "everyone is trying to help out the communities affected." "People are bringing blankets down to tent city … someone makes a call out on Facebook 'We need this,' there's several people responding to help out," he said. He says communities like Jean Marie River have seen people lose everything, and communities in the Sahtu and Beaufort Delta regions have yet to see the river rise like it did in the Dehcho region. Erasmus says workers in Fort Simpson have been working tirelessly, for 20 hours a day over the last week, to get the community's infrastructure back in shape. Erasmus said he doesn't have flood insurance, but he hopes the territorial government's emergency response will involve "stepping in to help affected homeowners out" with critical components like heat and water. As he rebuilds, he'll be looking to invest in more flood-resistant materials in the event the flooding comes once again.
"I didn't see any community workers being thanked," Justyn Boumah tells PEOPLE of why he set out to show them some appreciation
The musician is pushing classical music forward with her fusion of orchestral music and trap beats.
Hundreds of corpses have been found floating in the Ganges or buried in the sand of its banks.